behring

  1. T

    CSL Behring Receives FDA Approval Of HizentraTM, First 20 Percent Subcutaneous Immuno

    CSL Behring announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for HizentraTM, Immune Globulin Subcutaneous (Human), 20% Liquid, for treating patients diagnosed with primary immunodeficiency (PI). A once weekly immunoglobulin (Ig) replacement therapy...
    • tD33NAt
    • Thread
    • approval behring csl fda hizentratm immuno percent receives subcutaneous
    • Replies: 0
    • Forum: Health and Fitness
Back
Top